The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

23 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Functionalized N,N-Diphenylamines as Potent and Selective EPAC2 Inhibitors.EBI
University of Texas Medical Branch
Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists.EBI
University of Texas Medical Branch
Small molecule inhibitors targeting activator protein 1 (AP-1).EBI
University of Texas Medical Branch
Recent advances in the discovery of small molecules targeting exchange proteins directly activated by cAMP (EPAC).EBI
University of Texas Medical Branch
Identification and characterization of small molecules as potent and specific EPAC2 antagonists.EBI
University of Texas Medical Branch
5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP.EBI
University of Texas Medical Branch
Novel inhibitors of anthrax edema factor.EBI
University of Texas Medical Branch
Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides.EBI
University of Texas Medical Branch
Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators.EBI
University of Texas Medical Branch
Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.EBI
University of Texas Medical Branch
Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior.EBI
University of Texas Medical Branch
Discovery of phenanthridine analogues as novel chemical probes disrupting the binding of DNA to ΔFosB homodimers and ΔFosB/JunD heterodimers.EBI
University of Texas Medical Branch
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HTEBI
University of Texas Medical Branch
Mechanism of Action of an EPAC1-Selective Competitive Partial Agonist.EBI
University of Texas Medical Branch
Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists.EBI
University of Texas Medical Branch
Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.EBI
University of Texas Medical Branch
Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer.EBI
University of Texas Medical Branch
Synthesis and Biochemical Evaluation of Noncyclic Nucleotide Exchange Proteins Directly Activated by cAMP 1 (EPAC1) Regulators.EBI
University of Texas Medical Branch
Structure-activity relationships of 2-substituted phenyl-N-phenyl-2-oxoacetohydrazonoyl cyanides as novel antagonists of exchange proteins directly activated by cAMP (EPACs).EBI
University of Texas Medical Branch
Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets.EBI
University of Texas Medical Branch
Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation.EBI
University of Texas Medical Branch
Drug Discovery Targeting Bromodomain-Containing Protein 4.EBI
University of Texas Medical Branch
Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists.EBI
University of Texas Medical Branch